Pharmaceutical law in Bangladesh is built around the Drugs and Cosmetics Act 2023, which replaced the Drugs (Control) Ordinance 1982 and now governs the manufacture, import, export, distribution, sale, pricing, labelling and advertising of medicines and cosmetics. The Directorate General of Drug Administration (DGDA), under the Ministry of Health and Family Welfare, is the licensing authority and the main enforcement body for medicines.

Rules, guidelines and orders made under the Act fill in much of the detail, and some are still being developed or revised to reflect the new statute. National drug policy statements also guide the regulator on registration priorities and pricing. Anyone relying on older commentary written under the 1982 Ordinance should check whether the corresponding provision has been carried forward, changed or replaced before acting on it.

Each activity in the supply chain needs its own licence. Manufacturers require a manufacturing licence for the site, granted after inspection of premises, equipment, personnel and quality systems against good manufacturing practice standards. Importers, wholesalers and retail pharmacies need drug licences of the relevant category, and retail outlets must be supervised by qualified pharmacy personnel registered with the Pharmacy Council of Bangladesh.

Licences carry conditions and must be renewed on time. Changes of ownership, premises, key personnel or production lines may require prior notification or approval. Under pharmaceutical law in Bangladesh, operating outside the scope of a licence can lead to seizure of stock, suspension and prosecution, so licence scope should be checked before any new activity, product line or distribution channel is launched.

Every finished pharmaceutical product must be registered with the DGDA before it is manufactured for sale or imported. Applications include a dossier on composition, manufacturing, quality, stability, labelling and, for new molecules, safety and efficacy evidence. Expert committees advise the regulator on whether new products should be approved, and evidence of approval in reference countries can be relevant to that assessment.

The regulator has historically favoured local manufacture, which supplies most of the domestic market, and the import of finished products that are already produced locally has been restricted. Raw materials and active ingredients need separate import approval, which links to the registered products of the manufacturer. For foreign companies, pharmaceutical law in Bangladesh therefore often points towards local manufacture or contract manufacturing rather than direct import of finished goods.

The government fixes or approves prices for medicines, with tighter control over products on the essential medicines list and an approval process for the maximum retail price of others. Price changes require approval, and selling above the approved price is an offence. Pricing decisions can significantly affect the economics of a product, so price applications should be prepared with the same care as registration dossiers.

Labels and package inserts must contain prescribed information in the required languages and formats. Advertising of prescription medicines to the public is restricted, and promotional materials directed at healthcare professionals must be accurate and consistent with the approved product information. Under pharmaceutical law in Bangladesh, misleading claims can also engage consumer protection legislation and, where relevant, the Competition Act 2012.

Manufacturers and importers are responsible for the quality of the products they place on the market. The DGDA tests samples, inspects facilities and acts on complaints about substandard or falsified products. Holders of product registrations are expected to monitor adverse events, report safety signals and cooperate with investigations, and the regulator can require label changes, suspend registrations or order recalls.

A recall needs a clear plan: how affected batches are identified, how distributors and pharmacies are notified, how stock is retrieved and destroyed, and how the regulator is kept informed. Poorly managed recalls create regulatory, reputational and liability exposure at the same time, and distributors may later dispute who should bear the cost of retrieval and replacement stock. Companies operating under pharmaceutical law in Bangladesh should have written procedures in place before a problem arises.

Clinical trials of medicines in Bangladesh require ethical approval from a recognised research ethics committee, with the Bangladesh Medical Research Council playing a central role, and regulatory permission from the DGDA where investigational products are involved. Informed consent, trial registration, insurance or compensation arrangements for participants and the import of trial materials all need attention.

Sponsors and contract research organisations should document roles and responsibilities clearly in site and investigator agreements, including data ownership, publication rights, confidentiality and compliance with the data protection framework. Pharmaceutical law in Bangladesh treats research participants as a protected group, so departures from the approved protocol should be reported and managed promptly rather than corrected informally.

Bangladesh's pharmaceutical industry grew under the flexibility given to least developed countries under the WTO TRIPS Agreement, which allowed it to manufacture medicines without granting or enforcing pharmaceutical patents. The Patent Act 2023 modernised the patent system, but the treatment of pharmaceutical patents is closely linked to the country's scheduled graduation from least developed country status and to any transition arrangements.

As this transition takes effect, foreign originators will look to patent and regulatory protection in Bangladesh, and local producers will need to review their product pipelines for infringement risk. Licensing, technology transfer and voluntary licence arrangements are likely to become more important. This is one of the fastest changing areas of pharmaceutical law in Bangladesh and requires up-to-date advice on the current position.

Private hospitals, clinics and diagnostic laboratories require licences from the Directorate General of Health Services, which sets minimum standards for premises, equipment, staff and services. The legal framework for private healthcare facilities dates largely from the 1980s and has been the subject of reform proposals, so operators should confirm the current licensing requirements and fees before opening or expanding.

Doctors and dentists must be registered with the Bangladesh Medical and Dental Council, which also deals with professional misconduct. Diagnostic imaging using radiation needs separate approval from the nuclear regulatory authority. Hospitals that operate pharmacies need drug licences, so pharmaceutical law in Bangladesh and healthcare facility regulation overlap in daily operations.

The Drugs and Cosmetics Act 2023 brought cosmetics within the same statutory framework as medicines, so manufacturers and importers of cosmetics now face licensing, registration, labelling and quality obligations administered by the DGDA. Products that make therapeutic claims may be treated as medicines rather than cosmetics, which changes the approvals required. Classification should therefore be settled before a product is imported or marketed.

Medical devices and diagnostic reagents are increasingly subject to registration with the DGDA, and Unani, Ayurvedic, herbal and homoeopathic medicines have their own licensing and registration arrangements. Some products also need BSTI certification or import permits from other authorities. For borderline products, pharmaceutical law in Bangladesh rewards early engagement with the regulator, because reclassification after launch can lead to seizure of stock and costly relabelling.

Telemedicine platforms, online pharmacies and health apps sit at the boundary between medical practice, drug regulation, consumer protection and data protection. A platform that connects patients with doctors must ensure that the doctors are registered and that prescribing follows professional rules. Online sale of medicines raises licensing questions under pharmaceutical law in Bangladesh, particularly for prescription products and for delivery across districts.

Health information is sensitive personal data. The new data protection framework introduced in 2025 brings obligations on consent, security, breach response and cross-border transfers, with implementing rules still being developed. Hospitals and platforms should map where patient data is stored and who can access it, and should treat cloud contracts as regulated arrangements rather than routine IT procurement.

The pharmaceutical sector is generally open to foreign investment, and foreign-owned companies can register with Invest Bangladesh, which has taken over the investment registration functions formerly held by BIDA and BEZA. Acquisitions of local producers require careful regulatory due diligence, because the value of the target lies in its licences, product registrations, approved prices and inspection record, not only in its plant.

Change of control may need DGDA notification or approval for licences and registrations, and some approvals cannot be transferred without fresh application. Royalties, technical fees and dividends paid abroad must comply with Bangladesh Bank foreign exchange rules and tax withholding. Under pharmaceutical law in Bangladesh, contract manufacturing arrangements must keep regulatory responsibility clearly allocated between the brand owner and the manufacturer.

Pharmaceutical factories employ workers protected by the Bangladesh Labour Act 2006, while medical representatives and managerial staff may fall inside or outside the definition of worker depending on their functions. Distribution, agency and supply agreements should cover regulatory responsibilities, cold chain obligations, recall cooperation, exclusivity and termination, as well as anti-corruption controls for interactions with healthcare professionals.

Medicines receive specific VAT and duty treatment, raw material imports can attract concessions, and corporate tax rates and incentives are revised through annual finance legislation. Tax is often treated separately from pharmaceutical law in Bangladesh, but the two interact closely. Transfer pricing rules apply to related-party purchases of active ingredients and payments for brands or technology, and the NBR has examined these charges closely in audits.

The DGDA conducts inspections and sample testing, and mobile courts regularly take action against unlicensed pharmacies and the sale of unregistered, expired or counterfeit products. Offences under the drug legislation can result in fines, imprisonment, seizure and licence cancellation. Controlled substances are also subject to the Narcotics Control Act 2018, which brings separate licensing and enforcement by the Department of Narcotics Control.

Unlawful regulatory decisions can be challenged by writ under Article 102 of the Constitution. Commercial disputes with licensors, distributors and suppliers are resolved in the civil courts or by arbitration under the Arbitration Act 2001. Product liability and medical negligence claims may proceed through civil suits, consumer complaints or professional disciplinary routes, each with different evidential requirements. A coordinated strategy under pharmaceutical law in Bangladesh considers how a step in one forum affects the others.